Allergan’s Aczone Gel gets FDA approval

SILVER SPRING, Md. — The Food and Drug Administration has approved Allergan’s  Aczone (dapsone, 7.5) Gel. The gel is indicated to treat inflammatory and non-inflammatory acne in patients 12 years of age and older. 

 

The once-daily treatment uses a pump delivery system and tested on more than 2,000 patients in clinical trials. Allergan said that it expects the drug to be available in May 2016.